scholarly journals Apical myectomy for patients with hypertrophic cardiomyopathy and advanced heart failure

2020 ◽  
Vol 159 (1) ◽  
pp. 145-152 ◽  
Author(s):  
Anita Nguyen ◽  
Hartzell V. Schaff ◽  
Rick A. Nishimura ◽  
Jeffrey B. Geske ◽  
Joseph A. Dearani ◽  
...  
Author(s):  
Alberto Forteza ◽  
Juan Esteban de Villareal ◽  
Carlos Esteban Martín ◽  
Susana Mingo ◽  
Jessica García-Suárez ◽  
...  

2018 ◽  
Vol 2018 (3) ◽  
Author(s):  
Marta Farrero Torres ◽  
Felix Perez-Villa

[first paragraph of article]Hypertrophic cardiomyopathy has a broad spectrum of clinical presentations, from asymptomatic to patients with advanced heart failure and sudden death. Treatment options are limited, especially in non-obstructive forms. A minority of patients (around 3.5%) can progress to an end-stage state, characterized by systolic dysfunction and restrictive ventricular filling, related to extensive fibrotic replacement and chamber remodeling. In these cases, life expectancy is significantly reduced: a mean 3-year survival time has been reported.


2014 ◽  
Vol 7 (6) ◽  
pp. 967-975 ◽  
Author(s):  
Ethan J. Rowin ◽  
Barry J. Maron ◽  
Michael S. Kiernan ◽  
Susan A. Casey ◽  
David S. Feldman ◽  
...  

2015 ◽  
Vol 8 (6) ◽  
pp. 1014-1021 ◽  
Author(s):  
Daniele Pasqualucci ◽  
Alessandra Fornaro ◽  
Gabriele Castelli ◽  
Alessandra Rossi ◽  
Anna Arretini ◽  
...  

2021 ◽  
Author(s):  
Lin Qi ◽  
Zhengyi Shan ◽  
Ying Wei ◽  
Qing Yao Wang ◽  
Peng Zhao

Abstract BACKGROUND: Patients with hypertrophic cardiomyopathy (HCM) may develop concomitant advanced heart failure (HF). However, there is a paucity of data on the clinical outcomes of HCM patients without mutations who have advanced HF. Methods: A total of 1529 unrelated patients with HCM were enrolled and followed up. All patients were genotyped by whole exome or panel sequencing. Patients without mutations were studied to assess the impact of family history, clinical findings and echocardiographic parameters on advanced HF. Results: A total of 735unrelated patients with HCM were included in the study. The mean follow up duration was 3.2±2.3years. During follow-up,97 patients had advanced HF. Multivariable analysis revealed that risk factors significantly associated with advanced HF were gender [adjusted hazard ratio (HR)2.499, 95% confidence interval (CI) 1.531-4.081, P<0.001]and age at enrolment (adjusted HR 1.298,95% CI 1.00-1.682, P= 0.049) during the follow-up period. Conclusion: Female and older at enrolment can increase risk of advanced HF in gene-negative patients with HCM . Early detection and treatment have an important role to play in management and prevention of disease-related complications for gene-negative patients.


2003 ◽  
Vol 2 (1) ◽  
pp. 115-116
Author(s):  
J PARISSIS ◽  
S ADAMOPOULOS ◽  
K VENETSANOU ◽  
D MENTZIKOF ◽  
K KIRANAKOS ◽  
...  

2006 ◽  
Vol 5 (1) ◽  
pp. 149-149
Author(s):  
P MONTEIRO ◽  
J JONES ◽  
F FRANCO ◽  
C BAROSA ◽  
S COSTA ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document